Sign in
Taking people in United StatesNo phase

Studying immune fat cells and lipid handling in obesity and metabolic disease

Compares fat-tissue immune cells' fat handling in people with obesity and lean adults.

Key facts

Who runs it
Bettina Mittendorfer
Where
Columbia, United StatesSee the site
Trial code
Registry title
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
Status
Recruiting
People taking part
60 people, planned
Started
1 Aug 2024
Expected to end
Mar 2028
Type of study
Observational, 4 groups
Record updated
6 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a normal weight, or with obesity with or without fatty liver, insulin resistance or type 2 diabetes. It studies fat tissue immune cells.

Age
18 to 70 years
Sex
All
Disease stage
Four groups: lean (BMI ≥18.5 but <25.0 kg/m2); obesity with normal metabolism (BMI ≥30.0 but <45.0 kg/m2); obesity with insulin resistance and fatty liver (BMI ≥30.0 but <45.0 kg/m2, liver fat >7.5%); obesity with type 2 diabetes (BMI ≥30.0 but <45.0 kg/m2).
Earlier treatment
No medications or supplements known or suspected to affect glucose and lipid metabolism, except certain diabetes medicines in the type 2 diabetes group.
Biomarker or test result
Each group has set limits for liver fat, fasting blood glucose, blood glucose 2 hours after a 75 g glucose drink, and HbA1c.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Weight not stable, or not sedentary before enrollment
  • Use of tobacco products or excessive amounts of alcohol
  • Serious organ disease, such as chronic severe kidney disease or cancer
  • Not meeting all inclusion criteria

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • age: ≥18 but ≤70 years
  • not pregnant or breastfeeding
  • weight stable and sedentary before enrollment
  • no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity [MAO]-Type 2 Diabetes group)
  • no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer)
  • participants must fulfil all of the following group-specific inclusion criteria below:; Lean group:
  • Body mass index (BMI) ≥18.5 but <25.0 kg/m2
  • Intrahepatic triglyceride (IHTG) content <5%
  • fasting blood glucose concentration: <100 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: <140 mg/dl
  • Hemoglobin A1C (HbA1c) <5.7 %; Metabolically normal obesity (MNO) group:
  • BMI ≥30.0 but <45.0 kg/m2
  • IHTG content <5%
  • fasting blood glucose concentration: <100 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: <140 mg/dl
  • HbA1c <5.7 %; Metabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:
  • BMI ≥30.0 but <45.0 kg/m2
  • IHTG content >7.5%
  • fasting blood glucose concentration: ≥100 but <126 mg/dl
  • blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but <200 mg/dl
  • HbA1c: ≥5.7 but <6.4 %; MAO-type 2 diabetes group:
  • BMI ≥30.0 but <45.0 kg/m2
  • clinical diagnosis of type 2 diabetes or fasting blood glucose concentration >126 mg/dl or blood glucose concentration 2 h after a 75 g oral glucose challenge>200 mg/dl or HbA1c >6.4 % without medication if not diagnosed and medically treated for diabetes

Who cannot take part

  • Individuals that do not meet all inclusion Criterion

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • University of Missouri School of MedicineColumbia, United StatesContact: Bettina MittendorferTaking people

About the trial

What the trial wants to find out

The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.

Read full original descriptionShow less

Both groups will have:

* screening visit * imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging [MRI] and magnetic resonance spectroscopy [MRS] scans) * Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies

The 4 groups in the trial

  • Lean Individuals

    No intervention will be administered.

  • Metabolically abnormal obese Individuals

    Obesity with normoglycemia and abnormal liver fat content

  • Metabolically normal obese Individuals

    Obesity with normoglycemia and normal liver fat content

  • Individuals with Type 2 Diabetes Mellitus

    Pre-Diagnosed type 2 diabetics

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity-Associated Diseases
Plain-language title
Studying immune fat cells and lipid handling in obesity and metabolic diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06571474, who can take part
Record updated
6 August 2026